Summary
- With the sale of its infectious disease assets in 2018, The Medicines Company has become a one-candidate company.
- Management indicated that its three pivotal Phase 3 trials for inclisiran in the treatment of cardiovascular disease are on track to readout in 3Q19.
- A new CEO with launch experience has also been recently hired.
- With a late-2020 launch into a $20+ billion market and large, recent insider buying, The Medicines Company deserved a deeper dive.
- Looking for a portfolio of ideas like this one? Members of The Insiders Forum get exclusive access to our model portfolio. Start your free trial today »
Respect is tendered with pleasure only where it is not exacted.” - Anne Robert Jacques Turgot
Today, we take a look at a concern that is transforming itself with a new direction and CEO. The stock is well off its highs of last summer and seeing a large amount of recent insider buying.
Company Overview:
The Medicines Company (MDCO) is a Parsippany, New Jersey-based biopharmaceutical company focused on the treatment of atherosclerotic cardiovascular disease (ASCVD), the number one cause of death in the U.S. and worldwide. The company divested itself of all its infectious disease assets in 2018 to solely focus on its cholesterol lowering candidate, inclisiran. The Medicines Company (TMC) went public in 2000 at $16 per share. It currently employs ~62 and commands a market cap of ~$1.8 billion.
